BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PitchBoulder - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://pitchboulder.co
X-WR-CALDESC:Events for PitchBoulder
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260624T083000
DTEND;TZID=America/Chicago:20260624T103000
DTSTAMP:20260609T023805
CREATED:20260602T215930Z
LAST-MODIFIED:20260603T005929Z
UID:37556-1782289800-1782297000@pitchboulder.co
SUMMARY:Presenting: Arkana Therapeutics – Beyond GLP-1 Weight Loss
DESCRIPTION:Arkana Therapeutics — Co-Founder Jack Gugel presenting — is a biotechnology company developing next-generation obesity treatments inspired by nature’s most extreme metabolic adaptations. \nMore than 1 billion people worldwide are affected by obesity\, yet many patients discontinue GLP-1 therapies like Ozempic due to side effects or difficulty maintaining treatment. As a result\, weight regain remains a significant challenge and highlights the need for alternative therapies. \nArkana Therapeutics studies animals with unique metabolic traits\, such as the Burmese python\, to discover naturally evolved molecules that regulate appetite and energy balance. Their lead candidate\, ARK-100\, is an orally available appetite suppressant with a novel non-GLP-1 mechanism\, while ARK-200 is designed to increase energy expenditure through skeletal muscle metabolism. Together\, these programs aim to provide new options for obesity treatment with improved tolerability and long-term outcomes. \nOur target market is patients with obesity\, healthcare providers\, and pharmaceutical partners worldwide who need effective\, well-tolerated weight management therapies and are willing to pay for improved health outcomes and sustainable weight loss. \nOur competition is GLP-1 therapies such as Ozempic and Wegovy\, other obesity drug developers\, and metabolic disease biotech companies. Our competitive advantage is discovering therapeutics from naturally evolved biological systems and developing novel mechanisms that address obesity beyond traditional GLP-1 pathways. \nThe total market size in 2024 is the global obesity treatment market\, and the total market revenue in 2024 is $20B+\, with continued rapid growth expected. \nTop 3 challenges: \n\nRaising capital to advance clinical development\nBuilding a world-class scientific and operational team\nAdvancing the science and validating novel therapeutic mechanisms\n\nOur PitchBoulder ask: We’re looking for candid feedback on our pitch from both investors and operators. What parts of the story are compelling? What questions remain unanswered? Where can we improve clarity\, credibility\, or investor confidence as we continue building the company?
URL:https://pitchboulder.co/event/presenting-arkana-therapeutics-beyond-glp-1-weight-loss/
LOCATION:Galvanize Boulder\, 1023 Walnut St.\, Boulder\, CO\, 80302\, US
ATTACH;FMTTYPE=image/jpeg:https://pitchboulder.co/wp-content/uploads/2026/06/37556_image_highres_534544439.jpeg
ORGANIZER;CN="PitchBoulder":MAILTO:PitchBoulder-announce@messages.meetup.com
END:VEVENT
END:VCALENDAR